
06 Aug 2021
Bristol-Myers Squibb Co - Investment Thesis, Key Drivers, Financial & Price Forecasts, DCF Valuation
Bristol-Myers Squibb had another strong quarter with a particularly strong performance of its oncology drugs, Revlimid and Opdivo. After the Celgene acquisition, the pharmaceutical major’s largest chunk of revenues comes from these 2 cancer treatments and the blood thinning drug, Eliquis, which might gain excellent momentum in the coming quarters given the increasing application of blood thinners in Covid-19 treatments. Eliquis already grew by a staggering 29% in the last quarter and contributed ....

Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Bristol-Myers Squibb Co - Investment Thesis, Key Drivers, Financial & Price Forecasts, DCF Valuation
Bristol-Myers Squibb Company (BMY:NYS) | 0 0 0.0%
- Published:
06 Aug 2021 -
Author:
Ishan Majumdar -
Pages:
14 -
Bristol-Myers Squibb had another strong quarter with a particularly strong performance of its oncology drugs, Revlimid and Opdivo. After the Celgene acquisition, the pharmaceutical major’s largest chunk of revenues comes from these 2 cancer treatments and the blood thinning drug, Eliquis, which might gain excellent momentum in the coming quarters given the increasing application of blood thinners in Covid-19 treatments. Eliquis already grew by a staggering 29% in the last quarter and contributed ....